Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.60 |
| ▸ | LMNA | P02545 | 5/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | ADCY1 | Q08828 | 5/20 | 0.55 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.55 |
| ▸ | RAB9A | P51151 | 2/20 | 0.55 |
| ▸ | HTT | P42858 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | ADCY8 | P40145 | 3/20 | 0.53 |
| ▸ | LCLAT1 | Q6UWP7 | 4/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13571189 | 0.87 | LMNA (0.64) | KDM4ELMNASMN1; SMN2KMT2AADCY1 | |
| SCHEMBL13571245 | 0.87 | LMNA (0.64) | KDM4ELMNASMN1; SMN2KMT2AADCY1 | |
| SCHEMBL13571159 | 0.87 | LMNA (0.64) | KDM4ELMNASMN1; SMN2KMT2AADCY1 | |
| SCHEMBL13571361 | 0.86 | LMNA (0.63) | KDM4ELMNASMN1; SMN2KMT2AADCY1 | |
| SCHEMBL13571369 | 0.86 | ADCY1 (0.66) | KDM4ELMNASMN1; SMN2KMT2AADCY1 | |
| SCHEMBL13571428 | 0.84 | ADCY1 (0.67) | KDM4ELMNASMN1; SMN2KMT2AADCY1 | |
| SCHEMBL13571071 | 0.84 | LMNA (0.61) | KDM4ELMNASMN1; SMN2KMT2AADCY1 | |
| SCHEMBL13570971 | 0.84 | LMNA (0.72) | KDM4ELMNASMN1; SMN2KMT2AADCY1 | |
| SCHEMBL13571128 | 0.84 | LMNA (0.72) | KDM4ELMNASMN1; SMN2KMT2AADCY1 | |
| SCHEMBL13571330 | 0.84 | LMNA (0.72) | KDM4ELMNASMN1; SMN2KMT2AADCY1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8796320-B2 | 1,3,4-Oxadiazole-2-carboxamide compound | GENERAL INCORPORATED ASSOCIATION PHARMA VALLEY PROJECT SUPPORTING ORGANIZATION (JP) | 2014-08-05 | — | — | US | claimed |
| US-20120302524-A1 | 1,3,4-OXADIAZOLE-2-CARBOXAMIDE COMPOUND | GENERAL INCORPORATED ASSOCIATION PHARMA VALLEY PROJECT SUPPORTING ORGANIZATION (JP) | 2012-11-29 | — | — | US | claimed |
| EP-2520575-A1 | 1,3,4-OXADIAZOLE-2-CARBOXAMIDE COMPOUND | General Incorporated Association Pharma Valley Project Supporting Organization (JP) | 2012-11-07 | — | — | EP | claimed |
| EP-2520575-B1 | 1,3,4-OXADIAZOLE-2-CARBOXAMIDE COMPOUND | GEN INC ASS PHARMA VALLEY PROJECT SUPPORTING ORGANIZATION (JP) | 2016-11-30 | — | — | EP | disclosed |
| US-8796320-B2 | 1,3,4-Oxadiazole-2-carboxamide compound | GENERAL INCORPORATED ASSOCIATION PHARMA VALLEY PROJECT SUPPORTING ORGANIZATION (JP) | 2014-08-05 | — | — | US | disclosed |
| US-20120302524-A1 | 1,3,4-OXADIAZOLE-2-CARBOXAMIDE COMPOUND | GENERAL INCORPORATED ASSOCIATION PHARMA VALLEY PROJECT SUPPORTING ORGANIZATION (JP) | 2012-11-29 | — | — | US | disclosed |
| EP-2520575-A1 | 1,3,4-OXADIAZOLE-2-CARBOXAMIDE COMPOUND | General Incorporated Association Pharma Valley Project Supporting Organization (JP) | 2012-11-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120302524-A1 | 1,3,4-OXADIAZOLE-2-CARBOXAMIDE COMPOUND | STAT3, JAK2, STAT5A | KDM4E 480/4885LMNA 4594/4885SMN1; SMN2 3613/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.